Business context and reporting period
Immunome, Inc. is a pre-commercial biopharmaceutical company focused primarily on oncology and antibody discovery. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2023. The company reported no product sales; collaboration revenue came from its January 2023 AbbVie agreement.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Collaboration revenue | $4.3 million | None | $6.6 million | None |
| Research and development expense | $5.7 million | $5.7 million | $9.6 million | $13.8 million |
| General and administrative expense | $4.3 million | $3.2 million | $7.2 million | $6.8 million |
| Operating loss | $5.8 million | $8.9 million | $10.2 million | $20.6 million |
| Net loss | $5.6 million | $8.9 million | $9.8 million | $20.6 million |
| Basic and diluted loss per share | $0.46 | $0.74 | $0.81 | $1.70 |
- At June 30, 2023, cash and cash equivalents were $38.4 million; total current assets were $39.5 million and current liabilities $26.4 million. The filing reports no outstanding borrowings or debt balance.
- Deferred revenue was $23.4 million, including $17.7 million current and $5.7 million non-current. This is principally unearned revenue from AbbVie’s upfront payment, not debt.
- Six-month operating cash flow was positive $18.5 million, versus $14.4 million used in the prior-year period. It was driven mainly by a $23.4 million increase in deferred revenue, rather than operating profitability. Capital expenditures were $0.4 million; financing provided $34,000.
- No operating or gross margin is reported; the filing does not provide a clear value for these measures. Total liabilities were $32.1 million and stockholders’ equity $9.3 million at June 30.
Material changes versus the prior comparable period
- Revenue began under the AbbVie collaboration: $6.6 million recognized in the first half of 2023, versus none in 2022. The $30 million upfront payment is recognized over the estimated research period, not immediately; $23.4 million remained deferred at quarter-end.
- First-half R&D expense declined $4.2 million, mainly from reduced spending on the IMM-ONC-01 and IMM-BCP-01 programs, partly offset by AbbVie-related research spending. Q2 R&D expense was essentially unchanged year over year.
- First-half G&A rose $0.5 million, with higher legal and consulting fees related to the proposed Morphimmune merger. Q2 G&A increased $1.1 million year over year.
- Net loss narrowed in both periods, reflecting AbbVie revenue, lower first-half R&D expense, and higher interest income. The company remains loss-making.
Outlook, management commentary, risks and unusual items
- Management expected June 30 cash, excluding any merger-related financing proceeds, to fund operating expenses and capital expenditures for at least 12 months from the August 9, 2023 filing date. It also stated additional funding would be needed to advance its growth and R&D plans. The estimate depends on assumptions and capital may run out sooner.
- The June 29, 2023 merger agreement with Morphimmune was expected to close by year-end 2023, subject to conditions. The acquired programs include preclinical FA-TLR7a and 177 Lu-FAP development programs and Mi-1001. Management expected asset-acquisition accounting and anticipated expensing consideration allocated to acquired in-process R&D with no alternative future use.
- In connection with the proposed merger, investors agreed to purchase 21,690,871 shares for approximately $125 million, at $5.75 per share or $5.91 for affiliate investors. The PIPE was expected to close after the merger; proceeds were not included in the stated cash runway. Before the PIPE, existing Immunome and Morphimmune equityholders were expected to own approximately 55% and 45%, respectively, on the stated fully diluted basis.
- The AbbVie agreement covers discovery and validation of up to 10 target-antibody pairs. Potential payments of up to approximately $2.8 billion are contingent on research activity, options, development, sales and royalties; the filing cautions there is no assurance of payments beyond the $30 million upfront amount. AbbVie has termination rights, including for convenience.
- Management planned to submit an IND for lead oncology program IMM-ONC-01 in Q1 2024. Immunome had decided to seek a partner to continue the IMM-BCP-01 COVID-19 trial and further development.
- Key risks include clinical and regulatory uncertainty, reliance on partners and vendors, ability to raise capital, and potential delays or failure of development programs. If funding is insufficient, the company may reduce, delay or terminate programs or seek collaborations on less favorable terms.
- The filing reports no material litigation. Disclosure controls were concluded effective as of June 30, 2023, and no material change in internal control over financial reporting was reported.
Important facts for investors to verify
- Whether the Morphimmune merger and $125 million PIPE closed, and the resulting share count, dilution and cash position; neither transaction’s proceeds were included in the reported June 30 cash balance or runway estimate.
- Progress against the IMM-ONC-01 IND timeline and the partnering plan for IMM-BCP-01.
- AbbVie research milestones, option exercises and future payments: the stated potential $2.8 billion is contingent, not committed funding.
- Cash burn and liquidity excluding the deferred-revenue cash-flow benefit, and whether management’s runway assumptions remain valid.
- The filing contains inconsistent CARES Act employee-retention-credit descriptions: the notes say no such expense was recorded in 2023, while MD&A refers to credit-related expense effects in 2023. Clarify the period and accounting treatment.